PBAC's latest decision on Varicella zoster virus recombinant vaccine: Recommended with restriction (2023). Considered for Prevention of herpes zoster (shingles) in individuals aged 65 years and older, Aboriginal and Torres Strait Islander people aged 50 years and older, and immunocompromised people aged 18 years and older with specified high-risk medical conditions or therapies.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
3
first 2023
Submissions
3
2023 → 2023
Eligible population
People aged 65 years and older; Aboriginal and Torres Strait Islander people aged 50 years and older; immunocompromised people aged 18 years and older with specified high-risk conditions (haemopoietic stem cell transplant, solid organ transplant, haematological malignancy, advanced or untreated HIV) and immunocompromised individuals with additional conditions and therapies as defined by ATAGI (inborn errors of immunity, end-stage renal disease, B and T-cell targeted monoclonal antibody therapies, conventional immunosuppressive agents, biologic therapies, immunomodulatory drugs, and oral small molecule targeted therapies).
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
Registry
Primary endpoint
Other
Economic model
BIA only
Budget impact
$65M
ICER note
This is a vaccine submission for NIP listing; no cost-effectiveness ICER was calculated. The sponsor provided cost per dose and budget impact modelling rather than a traditional cost-utility analysis.
Submission history
Mar 2023: Recommended with restriction · Restricted
Jul 2023: Recommended with restriction · Restricted
Nov 2023: Recommended with restriction · Restricted